Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its members, a blow to rival Eli Lilly & Co.’s Zepbound that was moved off the ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Caremark negotiated an undisclosed lower ... meaning they can still decide to include Zepbound. Regardless, the CVS-Wegovy deal overshadowed an overall strong quarter for Eli Lilly.

Illinois officials indicated that the settlement is about a larger issue than just a contract dispute with one PBM.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...